Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for Cancer-Related Sleep Disturbances and Fatigue
NCT00792077Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2008
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in sleep disorder and fatigue, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Total Sleep Time at 8 weeks. Started Nov 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
sleep disorderfatigue
Beyond the preview
Go deeper on NCT00792077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792077.